Abstract

Objective To study the clinical effect of Longniu Bubi Granule on prevention and treatment of bone loss caused by premenopausal ovarian function suppression (OFS) combined with breast cancer aromatase inhibitor (AIs) . Methods Forty patients with postmenopausal and high risk of breast cancer treated with OFS combined with aromatase inhibitors were divided into treatment group (n=23) and control group (n=17) . The two groups were treated with calcium VitD3125IU, 1 tablet per day. The treatment group received the additional of Longniu Bugu Decoction, 2 doses daily, with continuous medication for 6 months. The bone mineral density (BMD) level, bone mineral density (T) and serum bone alkaline phosphatase (BALP) were measured before and 6 months after treatment. Results There were significant differences in lumbar (L2-4) and femoral neck bone mineral density, bone mineral density (T) and serum bone alkaline phosphatase (P<0.05) between the two groups after treatment, and the treatment group was superior to the control group. Conclusion Longniu Bugu Decoction can reduce bone loss in patients with premenopausal breast cancer caused by OFS combined with AIs therapy and improve patients’ life quality. Key words: Longniu Bugu Decoction; Premenopausal young high-risk breast cancer; Ovarian function inhibition combined with aromatase inhibitors; Bone loss

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.